Skip to main content
CCSB logo

CCSB — Investor Relations & Filings

Ticker · 1762 ISIN · TW0001762003 TW Manufacturing
Open in API
Filings indexed 1,608 across all filing types
Latest filing 2026-05-14 Interim / Quarterly Rep…
Country TW Taiwan
Listing TW 1762

About CCSB

www.ccsb.com.tw

Chunghwa Chemical Synthesis & Biotech Co., Ltd. (CCSB) is a specialized manufacturer of Active Pharmaceutical Ingredients (APIs) with a history dating back to 1964. The company focuses on the research, development, and large-scale production of high-quality APIs, particularly in the therapeutic areas of oncology, antifungal treatments, and immunosuppressants. CCSB offers a broad service portfolio that includes cGMP-compliant contract manufacturing and toll manufacturing. By leveraging advanced chemical synthesis and biotechnology platforms, the company provides tailored solutions to global pharmaceutical partners. CCSB adheres to rigorous international quality standards and environmental, health, and safety protocols, ensuring the reliable supply of critical medicinal components for the global healthcare market.

Recent filings

Filing Released Lang Actions
115年第1季海外子公司投資
Interim / Quarterly Report Classification · 80% confidence The document is a disclosure from Taiwan’s public information observation platform (公開資訊觀測站) for the company 中化生 under “115年1季申報作業” (Minguo Year 115 Q1 filing operations). It provides actual financial statement data on overseas subsidiary investments, including ending balances and recognized investment income. This is substantive financial content for a quarterly period, fitting the definition of an Interim/Quarterly Report rather than a simple announcement or annual report. Q1 2026
2026-05-14 Chinese
115年05月僑外投資持股
Regulatory Filings Classification · 92% confidence The document is a statutory form (“僑外及大陸地區投資人投資持股情形統計表”) filed to the public information observatory, showing aggregated foreign/Mainland China investor shareholding by security code/date. It is not an AGM presentation, financial report, share issue notice, or major individual insider notice, but rather a routine regulatory disclosure. It therefore falls under the fallback category “Regulatory Filings.”
2026-05-14 Chinese
115年第1季財務報告書 — 202601_1762_AI1.pdf
Interim / Quarterly Report Classification · 93% confidence The document is a consolidated interim financial report (“合併財務報告暨會計師核閱報告”) for the first quarter of the ROC years 115 and 114, prepared under IFRS 34 “Interim Financial Reporting.” It includes full interim financial statements (balance sheet, income statement, cash flows, and notes) and an auditor’s review report. This matches the definition of a comprehensive interim/quarterly report rather than a mere earnings release or report announcement. Therefore, it should be classified as an Interim/Quarterly Report. Q1 2026
2026-05-14 Chinese
115年第1季權益變動表
Interim / Quarterly Report Classification · 92% confidence The document is the consolidated statement of changes in equity (合併權益變動表) for the first quarter of the company’s fiscal year (民國115年第1季) containing detailed financial data and actual numbers. This makes it part of the interim/quarterly report rather than an announcement or summary. Therefore it should be classified as an Interim / Quarterly Report. Q1 2026
2026-05-14 Chinese
115年第1季現金流量表
Interim / Quarterly Report Classification · 86% confidence The document is a standalone consolidated cash flow statement for the first quarter of fiscal year 115 (2026) provided on the XBRL platform. It contains actual quarterly financial data and covers a period shorter than a full fiscal year. This meets the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-14 Chinese
115年第1季綜合損益表
Interim / Quarterly Report Classification · 90% confidence The document is a consolidated statement of comprehensive income with detailed financial line items for the first quarter (“115年第1季”) including revenues, costs, profits, taxes, EPS, etc. It provides actual financial data rather than simply announcing that a report is available. This matches the definition of a comprehensive interim/quarterly report (IR) rather than an earnings highlight (ER) or a report announcement (RPA). Therefore, it should be classified as an Interim / Quarterly Report (IR). Q1 2026
2026-05-14 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.